Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sNN0031 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| sNN0031 | EXPERIMENTAL | Continuous ICV infusion for two weeks at one of three dose levels |
| Placebo | PLACEBO_COMPARATOR | Continuous ICV infusion |
| Name | Type | Description |
|---|---|---|
| sNN0031 | DRUG | Continuous ICV infusion for two weeks |
| Placebo | DRUG | Continous ICV infusion |
Inclusion Criteria: * Male or female. Females should either be post-menopausal (at least 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with FSH levels \>40 mIU/mL), be surgically sterilized (bilateral oophorectomy w/o hysterectomy), or use adequate contraception (oral co...
sNN0031 is an investigational small molecule being studied for the treatment of Parkinson's Disease. It is administered intracerebroventricularly, meaning directly into the brain's ventricular system. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
sNN0031 is being developed by Medtronic plc, a medical technology company traded on the New York Stock Exchange under the ticker MDT. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug for Parkinson's Disease.
sNN0031 is in Phase 1 clinical development. A Phase 1 trial has been completed, which was designed to assess the safety and tolerability of the drug when administered intracerebroventricularly to patients with Parkinson's Disease. The drug remains investigational and is not yet approved.
sNN0031 has one completed clinical trial registered as NCT00866502, titled 'A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease'. This Phase 1 study enrolled 12 participants in Sweden and was placebo-controlled, randomized, and double-blind.
No alternative names for sNN0031 have been disclosed. The drug is identified solely by its code name sNN0031 in clinical trial registrations and development documentation. It is being studied specifically for Parkinson's Disease and is not known to be marketed under any other designation.